olmutinib

olmutinib (inn) ack jaanch-padtaal karane vaali cancer-rodhi dawa haye. yeh epidermal groth factor receptor (ee. jee. aff. aar.) key kinnez domen key paas ack cysteine avashesh key saath sahsanyojak bandhan dwara kaary kartaa haye. 
america mein, ise disambar 2015 mein gair-chhote koshika fefde key cancer (aine. aiss. see. ell. see.) mein ack safal chikitsa padnam diyaa gayaa thaa, aur dakshin koria mein, dawa koo maee 2016 mein mein key saath aine. aiss. see. ell. see. key doosari pankti key upchaar key liye anumodit kiya gayaa thaa. olmutinib key prati pratirodh kii soochana dee gaee haye; ack vyakti kaa cancer ee. jee. aff. aar. mein see. see utparivartan vikasit honey key baad aage badhana shuru hoe gayaa.
olmutinib kii khoj hainmi pharmaceutical dwara kii gaee thee aur 2015 mein bohringer ingelheim koo 50 million dollar key agrim bhugtan aur 680 million dollar taka key meal key patthar key saath ack samjhaute mein licenses praapt kiya gayaa thaa. navambar 2015 mein hanmi ney cheeni company zaai labs koo chean mein olmutinib bechane key liye ack vishesh licenses pradaan kiya.
30 sitambar, 2016 koo, koriyai niyaamak adhikaariyon ney olmutinib key baare mein ack suraksha chetavani jaari kii, jisamen usane vishaakt epidermal necrolysis key dou mamalon kaa varnan kiya, jinamen seey ack ghaatak thaa, aur stevens-johnson syndrome kaa ack mamla; bohringer ney usee dinn hainmi key saath apane saude koo samaapt karane kii ghoshana kii, yeh kahate hue kii nirnay dawa parr "sabhi upalabdh naidaanik detta" kii sameeksha key baad aaya, aur pratispardhi davaaon kaa bhee ullekh kiya.

